Talha Badar, Hematology Oncology based in Mayo Clinic, shared an article by Renato Bassan, et al. on X:
“Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study.
Upfront Blina after C3 ad C6 of consolidation, risk-adapted. Primary endpoint MRD-ve CR Results: 93% MRD-ve, 3 yrs OS blina treated pts 91%.”
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study.
Authors: Renato Bassan, et al.
